{"id":702655,"date":"2024-02-07T06:38:45","date_gmt":"2024-02-07T06:38:45","guid":{"rendered":"https:\/\/www.capgemini.com\/ca-fr\/?post_type=press-release&#038;p=702655"},"modified":"2025-03-30T04:21:20","modified_gmt":"2025-03-30T04:21:20","slug":"les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe","status":"publish","type":"press-release","link":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","title":{"rendered":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025"},"content":{"rendered":"\t\t<div class=\"wp-block-cg-blocks-hero-press-release\">\n\t\t\t<header class=\"header-hero-press-release\" role=\"main\" id=\"main-content-press-release\">\n\t\t\t\t<div class=\"container\">\n\t\t\t\t\t<div class=\"hero-press-release\">\n\t\t\t\t\t\t<div class=\"hero-press-release-content-wrapper\">\n\t\t\t\t\t\t\t<div class=\"row\">\n\t\t\t\t\t\t\t\t<div class=\"col-12\">\n\t\t\t\t\t\t\t\t\t<div class=\"header-title\">\n\t\t\t\t\t\t\t\t\t\t<h1>\n\t\t\t\t\t\t\t\t\t\t\tLes grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d&#8217;affaires dans la cr\u00e9ation d&#8217;environnements de laboratoire connect\u00e9s et de pointe d&#8217;ici \u00e0 2025\t\t\t\t\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"header-description\">\n\t\t\t\t\t\t\t\t\t\t<p>Les environnements de laboratoire de nouvelle g\u00e9n\u00e9ration sont d\u00e9sormais essentiels pour les th\u00e9rapies innovantes, la r\u00e9duction des d\u00e9lais de mise sur le march\u00e9 et l&#8217;am\u00e9lioration des taux d&#8217;approbation, mais la plupart d&#8217;entre eux sont encore en phase pilote.<\/p>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"header-date\">\n\t\t\t\t\t\t\t\t\t\t<span>f\u00e9vr. 7, 2024<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"hero-press-release-downloads\">\n\t\t\t\t\t\t\t\t<div class=\"row\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"col-12 col-md-6 col-lg-3\">\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"download-item\" type=\"download\" href=\"https:\/\/www.capgemini.com\/wp-content\/uploads\/2024\/02\/02_07_Lab-of-the-future_Group-news-alert.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-icon\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-details\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-title\">Download press release<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-props\">149 KB  pdf<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"col-12 col-md-6 col-lg-3\">\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"download-item\" type=\"download\" href=\"https:\/\/www.capgemini.com\/wp-content\/uploads\/2024\/02\/Final-Infographic-Lab-of-the-Future.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-icon\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-details\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-title\">Download infographic<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"download-props\">875 KB  pdf<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"hero-press-release-brand-image\">\n\t\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/themes\/capgemini2025\/assets\/images\/capgemini-research-institute-white.svg\" alt=\"Logo de la marque\" \/>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/header>\n\t\t<\/div>\n\t\t\n\n\n<section class=\"wp-block-cg-blocks-group undefined section section--article-content\"><div class=\"article-main-content\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-1\"><nav class=\"article-social\"><ul class=\"social-nav\"><li class=\"ip-order-fb\"><a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?=http:\/\/capgeminiucwe.develop\/?post_type=press-release&amp;p=179\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-fb\"><\/i><span class=\"sr-only\">Facebook<\/span><\/a><\/li><li class=\"ip-order-tw\"><a href=\"https:\/\/twitter.com\/intent\/tweet?=http:\/\/capgeminiucwe.develop\/?post_type=press-release&amp;p=179\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-tw\"><\/i><span class=\"sr-only\">Twitter<\/span><\/a><\/li><li class=\"ip-order-li\"><a href=\"https:\/\/www.linkedin.com\/shareArticle?=http:\/\/capgeminiucwe.develop\/?post_type=press-release&amp;p=179\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><span class=\"sr-only\">Linkedin<\/span><\/a><\/li><\/ul><\/nav><\/div><div class=\"col-12 col-md-11 col-lg-10\"><div class=\"article-text article-quote-text\">\n<p><strong>Paris, le 7 f\u00e9vrier 2024 &#8211; Les organisations pharmaceutiques repensent leur approche de la configuration et des op\u00e9rations de leurs laboratoires, en mettant l&#8217;accent sur l&#8217;acc\u00e9l\u00e9ration de la num\u00e9risation, l&#8217;exploitation de l&#8217;IA, l&#8217;am\u00e9lioration des processus et la mise en place des comp\u00e9tences et de la culture ad\u00e9quates pour une transformation des laboratoires. La n\u00e9cessit\u00e9 d&#8217;acc\u00e9l\u00e9rer les temps de cycle est le moteur du changement, la majorit\u00e9 (92 %) des organisations pharmaceutiques citant ce facteur parmi les principales motivations pour des laboratoires &#8221; next-gen &#8221; pr\u00eats pour l&#8217;avenir<\/strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">[1]<\/mark><strong>. C&#8217;est ce qui ressort du dernier rapport de l&#8217;institut de recherche Capgemini, intitul\u00e9 &#8220;<a href=\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/laboratoires-pharma-nouvelle-generation\/\">Building the next-gen pharma lab : Digitally connected, environmentally sustainable<\/a>&#8220;, qui explore l&#8217;\u00e9tat actuel de la transformation des laboratoires pharmaceutiques, les d\u00e9fis \u00e0 relever et les avantages attendus de la construction d&#8217;un laboratoire du futur.<\/strong><\/p>\n\n\n\n<p><strong>Les initiatives de transformation des laboratoires se multiplient<\/strong><\/p>\n\n\n\n<p>Selon l&#8217;\u00e9tude, les principaux moteurs de la transformation des laboratoires sont la n\u00e9cessit\u00e9 de d\u00e9velopper plus rapidement des m\u00e9dicaments innovants, la pression pour optimiser les co\u00fbts et l&#8217;exigence d&#8217;am\u00e9liorer les taux d&#8217;approbation des m\u00e9dicaments. En cons\u00e9quence, les organisations pharmaceutiques cherchent \u00e0 cr\u00e9er des laboratoires plus agiles, plus efficaces, plus collaboratifs et plus durables pour les aider \u00e0 mieux relever ces d\u00e9fis et \u00e0 r\u00e9aliser des perc\u00e9es scientifiques.<\/p>\n\n\n\n<p>Les grandes entreprises pharmaceutiques<mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">[2]<\/mark> pr\u00e9voient de presque doubler leur investissement dans la transformation des laboratoires d&#8217;ici 2025, pour atteindre jusqu&#8217;\u00e0 7 % de leur chiffre d&#8217;affaires, contre 4 % aujourd&#8217;hui. Pr\u00e8s de 75 % des entreprises pharmaceutiques ont d\u00e9j\u00e0 commenc\u00e9 \u00e0 moderniser leurs laboratoires, tandis que les autres planifient leur approche.<\/p>\n\n\n\n<p>&#8220;<em>Les entreprises pharmaceutiques sont aujourd&#8217;hui confront\u00e9es \u00e0 des d\u00e9fis sanitaires mondiaux de grande ampleur et un environnement de laboratoire de pointe peut les aider \u00e0 r\u00e9pondre aux exigences de l&#8217;industrie, en rendant les m\u00e9dicaments vitaux et les m\u00e9dicaments accessibles rapidement. Soutenus par la technologie et en constante \u00e9volution en termes de comp\u00e9tences, de processus et d&#8217;infrastructures, les laboratoires de nouvelle g\u00e9n\u00e9ration sont essentiels pour acc\u00e9l\u00e9rer le rythme des d\u00e9couvertes r\u00e9volutionnaires&#8221;,<\/em> a d\u00e9clar\u00e9 Thorsten Rall, Global Life Sciences Industry Lead chez Capgemini.<em> &#8221; L&#8217;opportunit\u00e9 pour les organisations r\u00e9side dans l&#8217;adoption r\u00e9ussie des derni\u00e8res technologies et le d\u00e9veloppement d&#8217;une strat\u00e9gie robuste, avec les donn\u00e9es et l&#8217;IA au c\u0153ur, afin de lib\u00e9rer tout le potentiel de la transformation de leur laboratoire &#8220;. Pour ceux qui cherchent \u00e0 cr\u00e9er et \u00e0 mettre \u00e0 l&#8217;\u00e9chelle des laboratoires de nouvelle g\u00e9n\u00e9ration, la cl\u00e9 reste dans la conception centr\u00e9e sur l&#8217;humain, avec des scientifiques positionn\u00e9s au centre de ce processus<\/em>.&#8221;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a id=\"_ftn1\" href=\"#_ftnref1\">[1]<\/a> &nbsp;Les laboratoires de nouvelle g\u00e9n\u00e9ration sont des laboratoires qui font \u00e9voluer en permanence leur technologie, leur infrastructure, leurs m\u00e9thodes de travail, leurs comp\u00e9tences et leur culture.<\/p>\n\n\n\n<p><a id=\"_ftn2\" href=\"#_ftnref2\">[2]<\/a> Les grandes entreprises pharmaceutiques sont d\u00e9finies comme celles dont le chiffre d&#8217;affaires annuel est sup\u00e9rieur ou \u00e9gal \u00e0 10 milliards de dollars.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n<div class=\"wp-block-cg-blocks-cg-block-related-content\"><section class=\"relatedContentBlock\"><div class=\"container\"><div class=\"row\"><div class=\"content-title col-12 col-md-8\"><h2 class=\"related-content-heading\">Autres publications<\/h2><\/div><\/div><div class=\"row relatedContent\"><div class=\"col-lg-4 col-md-6 col-xs-12\">\n\t\t\t\t\t\t\t<div class=\"box\">\n\t\t\t\t\t\t\t\t<a aria-label=\"Lire la suite Passant de l\u2019engouement \u00e0 une approche plus r\u00e9aliste, les organisations augmentent leurs investissements en IA et visent la cr\u00e9ation de valeur \u00e0 long terme\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/passant-de-lengouement-a-une-approche-plus-realiste-les-organisations-augmentent-leurs-investissements-en-ia-et-visent-la-creation-de-valeur-a-long-terme\/\" class=\"anchorWrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"box-tag\"><span>Publications<\/span><\/span>\n\t\t\t\t\t\t\t\t\t<div class=\"box-title\"><h3 class=\"box-subtitle\">Passant de l\u2019engouement \u00e0 une approche plus r\u00e9aliste, les organisations augmentent leurs investissements en IA et visent la cr\u00e9ation de valeur \u00e0 long terme<\/h3><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-date\">\n\t\t\t\t\t\t\t\t\t\t<span>Mar 11, 2026<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-bottom\">\n\t\t\t\t\t\t\t\t\t\t&lt;a class=&quot;link-download&quot; href=&quot;https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2026\/01\/01_15-Capgemini-AI-perspectives-and-AI-in-CXO-decision-making-press-release_FR.pdf&quot; aria-label=&quot;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&quot; target=&quot;_blank&quot;  type=&quot;download&quot; title=&quot;Opens in a new window&quot;&gt;\n\t\t\t\t\t\t\t&lt;span&gt;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&lt;\/span&gt;\n\t\t\t\t\t\t\t&lt;span&gt;174 KB PDF&lt;\/span&gt;\n\t\t\t\t\t\t&lt;\/a&gt;\n\t\t\t\t\t\t\t\t\t\t<a class=\"more\" aria-label=\"Lire la suite Passant de l\u2019engouement \u00e0 une approche plus r\u00e9aliste, les organisations augmentent leurs investissements en IA et visent la cr\u00e9ation de valeur \u00e0 long terme\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/passant-de-lengouement-a-une-approche-plus-realiste-les-organisations-augmentent-leurs-investissements-en-ia-et-visent-la-creation-de-valeur-a-long-terme\/\">Lire la suite<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div><div class=\"col-lg-4 col-md-6 col-xs-12\">\n\t\t\t\t\t\t\t<div class=\"box\">\n\t\t\t\t\t\t\t\t<a aria-label=\"Lire la suite Observatoire Mondial des March\u00e9s de l\u2019\u00c9nergie (WEMO)\u00a02023 de Capgemini\u00a0\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/observatoire-mondial-des-marches-de-lenergie-wemo-2023-de-capgemini-2\/\" class=\"anchorWrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"box-tag\"><span>Publications<\/span><\/span>\n\t\t\t\t\t\t\t\t\t<div class=\"box-title\"><h3 class=\"box-subtitle\">Observatoire Mondial des March\u00e9s de l\u2019\u00c9nergie (WEMO)\u00a02023 de Capgemini\u00a0<\/h3><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-date\">\n\t\t\t\t\t\t\t\t\t\t<span>Feb 21, 2026<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-bottom\">\n\t\t\t\t\t\t\t\t\t\t&lt;a class=&quot;link-download&quot; href=&quot;https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2023\/11\/2023_11_28_Capgemini_WEMO_FR.pdf&quot; aria-label=&quot;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&quot; target=&quot;_blank&quot;  type=&quot;download&quot; title=&quot;Opens in a new window&quot;&gt;\n\t\t\t\t\t\t\t&lt;span&gt;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&lt;\/span&gt;\n\t\t\t\t\t\t\t&lt;span&gt;137 KB PDF&lt;\/span&gt;\n\t\t\t\t\t\t&lt;\/a&gt;\n\t\t\t\t\t\t\t\t\t\t<a class=\"more\" aria-label=\"Lire la suite Observatoire Mondial des March\u00e9s de l\u2019\u00c9nergie (WEMO)\u00a02023 de Capgemini\u00a0\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/observatoire-mondial-des-marches-de-lenergie-wemo-2023-de-capgemini-2\/\">Lire la suite<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div><div class=\"col-lg-4 col-md-6 col-xs-12\">\n\t\t\t\t\t\t\t<div class=\"box\">\n\t\t\t\t\t\t\t\t<a aria-label=\"Lire la suite Les acteurs industriels europ\u00e9ens et am\u00e9ricains pr\u00e9voient d\u2019investir 3.400 milliards de dollars pour la r\u00e9industrialisation au cours des trois prochaines ann\u00e9es\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-acteurs-industriels-europeens-et-americains-prevoient-dinvestir3-400-milliards-de-dollars-pour-la-reindustrialisation-au-cours-des-trois-prochaines-annees\/\" class=\"anchorWrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"box-tag\"><span>Publications<\/span><\/span>\n\t\t\t\t\t\t\t\t\t<div class=\"box-title\"><h3 class=\"box-subtitle\">Les acteurs industriels europ\u00e9ens et am\u00e9ricains pr\u00e9voient d\u2019investir 3.400 milliards de dollars pour la r\u00e9industrialisation au cours des trois prochaines ann\u00e9es<\/h3><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-date\">\n\t\t\t\t\t\t\t\t\t\t<span>Apr 18, 2024<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"box-bottom\">\n\t\t\t\t\t\t\t\t\t\t&lt;a class=&quot;link-download&quot; href=&quot;https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2024\/04\/2024_04_18_Capgemini-Press-Release_Reindustrialization_of_Europe-and-the-US-report_FR.pdf&quot; aria-label=&quot;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&quot; target=&quot;_blank&quot;  type=&quot;download&quot; title=&quot;Opens in a new window&quot;&gt;\n\t\t\t\t\t\t\t&lt;span&gt;T\u00e9l\u00e9charger le communiqu\u00e9 de presse&lt;\/span&gt;\n\t\t\t\t\t\t\t&lt;span&gt;162 KB PDF&lt;\/span&gt;\n\t\t\t\t\t\t&lt;\/a&gt;\n\t\t\t\t\t\t\t\t\t\t<a class=\"more\" aria-label=\"Lire la suite Les acteurs industriels europ\u00e9ens et am\u00e9ricains pr\u00e9voient d\u2019investir 3.400 milliards de dollars pour la r\u00e9industrialisation au cours des trois prochaines ann\u00e9es\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-acteurs-industriels-europeens-et-americains-prevoient-dinvestir3-400-milliards-de-dollars-pour-la-reindustrialisation-au-cours-des-trois-prochaines-annees\/\">Lire la suite<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div><\/div><\/div><\/section><\/div>","protected":false},"excerpt":{"rendered":"<p>Les organisations pharmaceutiques repensent leur approche de la configuration et des op\u00e9rations de leurs laboratoires, en mettant l&#8217;accent sur l&#8217;acc\u00e9l\u00e9ration de la num\u00e9risation, l&#8217;exploitation de l&#8217;IA, l&#8217;am\u00e9lioration des processus et la mise en place des comp\u00e9tences et de la culture ad\u00e9quates pour une transformation des laboratoires. <\/p>\n","protected":false},"author":387,"featured_media":702656,"template":"","meta":{"cg_dt_proposed_to":[],"cg_seo_hreflang_relations":"[]","cg_seo_canonical_relation":"","cg_seo_hreflang_x_default_relation":"{\"uuid\":\"0cef272c-85c5-43a3-b16c-5ddf5bcdd838\",\"blogId\":\"\",\"domain\":\"\",\"sitePath\":\"\",\"postLink\":\"\",\"postId\":null,\"isSaved\":true,\"isCrossLink\":false,\"hasCrossLink\":false}","cg_dt_approved_content":true,"cg_dt_mandatory_content":false,"cg_dt_notes":"","cg_dg_source_changed":true,"cg_dt_link_disabled":false,"footnotes":"","related_resource_url":"https:\/\/www.capgemini.com\/wp-content\/uploads\/2024\/02\/02_07_Lab-of-the-future_Group-news-alert.pdf","related_resource_id":990351,"related_resource_size":"149 KB","related_resource_type":"pdf","cg_author":0,"featured_focal_points":""},"tags":[],"press-release-type":[239],"brand":[166],"class_list":["post-702655","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","press-release-type-publications","brand-capgemini-research-institute"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.8 (Yoast SEO v22.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025 - Capgemini Canada French<\/title>\n<meta name=\"description\" content=\"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d&#039;environnements de laboratoire connect\u00e9s et de pointe d&#039;ici \u00e0 2025\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025\" \/>\n<meta property=\"og:description\" content=\"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d&#039;environnements de laboratoire connect\u00e9s et de pointe d&#039;ici \u00e0 2025\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\" \/>\n<meta property=\"og:site_name\" content=\"Capgemini Canada French\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-30T04:21:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2025\/10\/New-Web-preview-global.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\",\"name\":\"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025 - Capgemini Canada French\",\"isPartOf\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg\",\"datePublished\":\"2024-02-07T06:38:45+00:00\",\"dateModified\":\"2025-03-30T04:21:20+00:00\",\"description\":\"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d'environnements de laboratoire connect\u00e9s et de pointe d'ici \u00e0 2025\",\"breadcrumb\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg\",\"contentUrl\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.capgemini.com\/ca-fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Releases\",\"item\":\"https:\/\/www.capgemini.com\/ca-fr\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/#website\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/\",\"name\":\"Capgemini Canada French\",\"description\":\"Capgemini\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.capgemini.com\/ca-fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025 - Capgemini Canada French","description":"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d'environnements de laboratoire connect\u00e9s et de pointe d'ici \u00e0 2025","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","og_locale":"fr_FR","og_type":"article","og_title":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025","og_description":"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d'environnements de laboratoire connect\u00e9s et de pointe d'ici \u00e0 2025","og_url":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","og_site_name":"Capgemini Canada French","article_modified_time":"2025-03-30T04:21:20+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2025\/10\/New-Web-preview-global.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","url":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","name":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025 - Capgemini Canada French","isPartOf":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage"},"image":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg","datePublished":"2024-02-07T06:38:45+00:00","dateModified":"2025-03-30T04:21:20+00:00","description":"Les grandes entreprises pharmaceutiques investiront dans la cr\u00e9ation d'environnements de laboratoire connect\u00e9s et de pointe d'ici \u00e0 2025","breadcrumb":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#primaryimage","url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg","contentUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.capgemini.com\/ca-fr\/"},{"@type":"ListItem","position":2,"name":"Press Releases","item":"https:\/\/www.capgemini.com\/ca-fr\/news\/"},{"@type":"ListItem","position":3,"name":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.capgemini.com\/ca-fr\/#website","url":"https:\/\/www.capgemini.com\/ca-fr\/","name":"Capgemini Canada French","description":"Capgemini","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.capgemini.com\/ca-fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025","url":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/"},"thumbnailUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg?w=150&h=150&crop=1","image":{"@type":"ImageObject","url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg"},"articleSection":"Uncategorized","author":[],"creator":[],"publisher":{"@type":"Organization","name":"Capgemini Canada French","logo":""},"keywords":[],"dateCreated":"2024-02-07T06:38:45Z","datePublished":"2024-02-07T06:38:45Z","dateModified":"2025-03-30T04:21:20Z"},"rendered":"<meta name=\"parsely-title\" content=\"Les grandes entreprises pharmaceutiques investiront pr\u00e8s de 7% de leur chiffre d\u2019affaires dans la cr\u00e9ation d\u2019environnements de laboratoire connect\u00e9s et de pointe d\u2019ici \u00e0 2025\" \/>\n<meta name=\"parsely-link\" content=\"https:\/\/www.capgemini.com\/ca-fr\/actualites\/communiques-de-presse\/les-grandes-entreprises-pharma-investiront-dans-la-construction-de-labo-de-pointe\/\" \/>\n<meta name=\"parsely-type\" content=\"post\" \/>\n<meta name=\"parsely-image-url\" content=\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg?w=150&amp;h=150&amp;crop=1\" \/>\n<meta name=\"parsely-pub-date\" content=\"2024-02-07T06:38:45Z\" \/>\n<meta name=\"parsely-section\" content=\"Uncategorized\" \/>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/capgemini.com\/p.js"},"archive_status":false,"featured_image_src":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2024\/02\/test-3.jpg","featured_image_alt":"","jetpack_sharing_enabled":true,"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Capgemini Canada French","distributor_original_site_url":"https:\/\/www.capgemini.com\/ca-fr","push-errors":false,"tag_names":[],"_links":{"self":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/press-release\/702655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/types\/press-release"}],"author":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/users\/387"}],"version-history":[{"count":3,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/press-release\/702655\/revisions"}],"predecessor-version":[{"id":707381,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/press-release\/702655\/revisions\/707381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/media\/702656"}],"wp:attachment":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/media?parent=702655"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/tags?post=702655"},{"taxonomy":"press-release-type","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/press-release-type?post=702655"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/brand?post=702655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}